Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial). This is an ASCO ...
KRd showed superior PFS and deeper responses compared to VRd in newly diagnosed multiple myeloma patients, achieving higher complete response and MRD-negativity rates. The trial demonstrated ...
Carfilzomib-based quadruplet regimens are producing deep responses and high MRD negativity in NDMM, challenging bortezomib-based standards. KRd regimens show strong activity in both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results